drugset / Trial / NCT03257592

Positron Emission Tomography (PET) Imaging of Glial Activation in Psychotic Disease States

NCT03257592 ↗

Phase 1 Terminated 35 enrolled Johns Hopkins University
Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

Many neurological diseases, including AIDS dementia, Alzheimer's disease and schizophrenia, involve an inflammatory component thought to specifically involve glial cell activation. The Investigators has been concerned with the development of tools for noninvasive imaging of inflammatory processes in psychotic disease. Here, the investigators aim to use PET-based neuroimaging with carbon-11 N,N-diethyl-2-(4-methoxyphenyl)-5,7-dimethylpyrazolo\[1,5-a\]pyrimidine-3-acetamide, (\[11C\]DPA)-713 to quantify regional distribution of translocator protein (TSPO), a putative marker of inflammation, in the brains of patients with schizophrenia and bipolar disorder, type I. The investigators will focus on patients in the early stages of disease (within first five years of onset of schizophrenia diagnosis and within first five years of first manis, respectively) to minimize the confounds of age-, chronic illness-, and medication- effects on our results.

Timeline

Start
2010-08
Primary completion
2018-04
Completion
2018-04

Outcome

Outcome not reported

Stopped (Business): “Lack of funding”

Drugs

EvaluationDrugModalityDoseRoute
Subject [11C]DPA-713 Diagnostic / imaging agent — —